Economic Evaluation of Different Organizational Models for the Management of Patients with Hepatitis C
BACKGROUND: Access to Directly Acting Antivirals (DAAs) for Hepatitis C Virus (HCV) treatment in Italy was initially restricted to severe patients. In 2017, AIFA expanded access to all patients, to achieve elimination by 2030.
AIM: To investigate the impact of different hospitals’ organizational models on elimination timing, treatment capacity and direct costs.
METHODS: Most Regional healthcare systems in Italy deploy a Center of Excellence (CoE) organizational model, where patients are referred to a single major hospital in the area, which is the only one that can prescribe and deliver DAAs. The study was conducted at Bergamo’s (Lombardy, Italy) Papa Giovanni XXIII hospital (PG-23), which deploys a Hub&Spoke model: the Hub (PG-23) prescribes and delivers DAAs while Spokes (four smaller hospitals) can only prescribe them. The study compares the two models (CoE vs. H&S). Patient journey and workloads were mapped and quantified through interviews with hospital stakeholders. Cost data were collected through the hospital’s IT system; the sample comprised 2,277 HCV patients, over one year.
RESULTS: The study calculated the average cost to treat HCV patients (~ € 1,470 per patient). Key cost drivers are lab tests (60%) and specialist visits (30%). Over one year, H&S can treat 68% more patients than CoE. As deferred patients absorb up to 40% of total costs, the “Optimized” model was designed by streamlining specialists’ visits and involving general practitioners during follow-up. “Optimized” model increases treatment capacity and reduces costs of deferred patients by 72% vs CoE.
CONCLUSION: The study demonstrates the importance of organizational models in efficiently achieving 2030 elimination.
World Health Organization. Hepatitis C. Fact sheet. Updated April 2017. Available at http://www.who.int/mediacentre/factsheets/fs164/en/ (last accessed August 2017)
World Health Organization. Towards access 2030 – Medicine and Health Products program strategic Framework 2016-2030. Available at http://www.who.int/medicines/publications/towards_access2030/en/ (last accessed August 2017)
ISTAT. Le principali cause di morte in Italia. Anno 2012. Available at: https://www.istat.it/it/files/2014/12/Principali_cause_morte_2012.pdf (last accessed July 2017)
Wilkins T, Malcolm JK, Raina D, et al. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010; 81: 1351-7
Poordad F, McCone J Jr, Bacon BR, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206; http://dx.doi.org/10.1056/NEJMoa1010494
Lange CM, Jacobson IM, Rice CM, et al. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 2014; 6: 4-15; http://dx.doi.org/10.1002/emmm.201303131
Agenzia Italiana Del Farmaco. Bacheca atti amministrativi regionali. Available at http://www.aifa.gov.it/content/bacheca-atti-amministrativi-regionali (last accessed August 2017)
Agenzia Italiana Del Farmaco. Nuovo algoritmo per la terapia dell’epatite C cronica. Available at http://www.agenziafarmaco.gov.it/content/l%E2%80%99aifa-pubblica-il-nuovo-algoritmo-la-terapia-dell%E2%80%99epatite-c-cronica (last accessed December 2017)
Regione Lombardia. Approvazione del documento di indirizzo per la gestione del nuovi farmaci antivirali per la terapia dell’epatite C cronica e per l’attivazione della rete regionale HCV. Decreto n. 7826 del 28/09/2015
Agenzia Italiana Del Farmaco. Ridefinizione dei criteri di trattamento per la terapia dell’Epatite C cronica. Determina n. 500/2017 del 24/03/2017. GU n.75 del 30-3-2017
Kondili LA, Romano F, Rolli FR, et al.; PITER Collaborating Group. Modeling Cost-Effectiveness and Health Gains of a “Universal” Versus “Prioritized” Hepatitis C Virus Treatment Policy in a Real-Life Cohort. Hepatology 2017; 66: 1814-25; http://dx.doi.org/10.1002/hep.29399
Agenzia Italiana Del Farmaco. Aggiornamento epatite C. Available at http://www.agenziafarmaco.gov.it/content/aggiornamento-epatite-c (last accessed August 2017)
Lanati EP, Lidonnici D, Gasbarrini A, et al. Cohort of HCV patients in Italy: sizing and treatments in a sample of Italian. ISPOR 17th Annual European Congress. Amsterdam: 2014
Rizzetto M. Un modello esportabile per l’eliminazione di HCV in Italia. ReAd files 2018; 19: 46-9
Copyright (c) 2019 Stefano Fagiuoli, Luisa Pasulo, Franco Maggiolo, Rosaria Spinella, Paolo Del Poggio, Roberto Boldizzoni, Mariella Di Marco, Alessandro Aronica, Chiara Benedetti, Paolo Correale, Chiara Garavaglia, Carlo Nicora
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
HTML: 56 views
PDF: 34 views